Address correspondence to Andrew Escayg, Department of Human Genetics, Emory University, Atlanta, Georgia 30322, U.S.A. E-mail: email@example.com or Alan Goldin, Department of Microbiology and Molecular Genetics, University of Calivornia, Irvine, CA 92697, U.S.A. E-mail: firstname.lastname@example.org
Mutations in a number of genes encoding voltage-gated sodium channels cause a variety of epilepsy syndromes in humans, including genetic (generalized) epilepsy with febrile seizures plus (GEFS+) and Dravet syndrome (DS, severe myoclonic epilepsy of infancy). Most of these mutations are in the SCN1A gene, and all are dominantly inherited. Most of the mutations that cause DS result in loss of function, whereas all of the known mutations that cause GEFS+ are missense, presumably altering channel activity. Family members with the same GEFS+ mutation often display a wide range of seizure types and severities, and at least part of this variability likely results from variation in other genes. Many different biophysical effects of SCN1A-GEFS+ mutations have been observed in heterologous expression systems, consistent with both gain and loss of channel activity. However, results from mouse models suggest that the primary effect of both GEFS+ and DS mutations is to decrease the activity of GABAergic inhibitory neurons. Decreased activity of the inhibitory circuitry is thus likely to be a major factor contributing to seizure generation in patients with GEFS+ and DS, and may be a general consequence of SCN1A mutations.
The epilepsies are a diverse collection of neurologic disorders involving recurrent and unprovoked seizures that are the manifestation of abnormal electrical activity in the central nervous system (CNS), and they represent one of the most common neurologic diseases, with a lifetime incidence of up to 3% in the general population (Hauser et al., 1993). Although many epilepsies are secondary to injury or another disease, approximately 40% are idiopathic, meaning that the underlying cause is unknown (Steinlein, 2002). It is presumed that most of the idiopathic epilepsies result from genetic abnormalities, with the majority likely caused by mutations in multiple currently unidentified genes. Nevertheless, research has uncovered a growing number of single-gene mutations that cause epilepsy (Noebels, 2003). The majority of these genes encode ion channels or receptors, including voltage-gated sodium, potassium, calcium, and chloride channels and receptors for acetylcholine and γ-aminobutyric acid (GABA). Even in these cases, however, the mechanisms by which the defects cause epilepsy are not well understood.
It seems logical that mutations in voltage-gated sodium channels would cause epilepsy, because these channels are in part responsible for controlling electrical excitability. Membrane depolarization activates the channel, causing a voltage-dependent conformational change that increases the permeability to sodium ions, further depolarizing the cell. This is followed by inactivation, in which the channel closes and the permeability to sodium ions decreases, allowing the membrane potential to return to its resting level. The sodium channel protein consists of a highly processed ∼260-kDa α subunit that comprises four homologous domains termed I–IV (Fig. 1). Within each domain, there are six transmembrane segments called S1–S6. A hairpin-like P-loop between S5 and S6 forms part of the channel pore, and the intracellular loop that connects domains III and IV forms the inactivation gate (Catterall, 2000). Channels in the adult CNS are associated with accessory β1, β2, β3, or β4 subunits. The β subunits are expressed in a complementary fashion, so that α subunits in the CNS are associated with either β1 or β3, and β2 or β4 (Isom et al., 1994; Morgan et al., 2000; Yu et al., 2003). Each β subunit consists of a single transmembrane segment, an extracellular immunoglobulin (Ig)–like loop, and an intracellular C-terminus (Fig. 1). The β2 or β4 subunit is covalently linked to the α subunit by a disulfide bond (Messner & Catterall, 1985), and the β1 or β3 subunit is noncovalently attached. The voltage dependence, kinetics, and localization of the α subunits are modulated by interactions with the β subunits.
The mammalian voltage-gated sodium channel α subunits are encoded by nine genes, termed SCN1A through SCN11A (SCN6A and SCN7A represent the same gene that encodes a non–voltage-gated sodium channel). The genes encode nine distinct isoforms, termed Nav1.1 through Nav1.9 (Goldin et al., 2000; Goldin, 2002). Four isoforms are expressed at high levels in the CNS (Nav1.1, Nav1.2, Nav1.3, and Nav1.6), and four are expressed at high levels in the peripheral nervous system (Nav1.6, Nav1.7, Nav1.8, and Nav1.9). The remaining two isoforms are expressed predominantly in adult skeletal muscle (Nav1.4) and in embryonic skeletal muscle and heart muscle (Nav1.5). The isoforms in the CNS are present at different times in development and in different locations (Trimmer & Rhodes, 2004). Nav1.1 becomes detectable shortly after birth and increases until adulthood (Beckh et al., 1989). Nav1.2 becomes detectable during embryonic development and reaches maximal levels during adulthood (Beckh et al., 1989). Nav1.3 is often considered an embryonic isoform, because its expression peaks at birth and it is usually undetectable in adult rodents (Beckh et al., 1989), but it has been detected at low levels in adulthood in humans (Whitaker et al., 2001). Nav1.3 expression has also been observed in the adult rat nervous system after dorsal root ganglion injury (Black et al., 1999; Hains et al., 2003) and in some epileptic rodent models (Yu et al., 2006; Guo et al., 2008). Nav1.6 is expressed during late embryonic and early postnatal periods (Felts et al., 1997; Schaller & Caldwell, 2000) and is also present at high levels during adulthood (Schaller et al., 1995).
Because of their distinct subcellular distribution and functional properties, each sodium channel isoform most likely plays a unique role in the initiation and propagation of action potentials. For example, action potentials are initiated preferentially at the distal end of the axon initial segment compared to the proximal end. This preference may reflect the high density of Nav1.6 channels in the distal end compared to the high density of Nav1.2 channels in the proximal end, as Nav1.6 channels have a lower threshold for activation (Hu et al., 2009). Because Nav1.1 is clustered at the axon initial segments of parvalbumin-positive basket cells (Ogiwara et al., 2007), which project their terminal axonal arbors around the soma and proximal dendrites of excitatory neurons, it may play an important role in modulating excitability of the network.
Epilepsy Syndromes Caused by SCN1A Mutations
Mutations in three of the sodium channel α subunit genes that are mainly expressed in the CNS have been shown to cause epilepsy in humans. Mutations in SCN1A (Nav1.1) and SCN2A (Nav1.2) cause several subtypes of dominant idiopathic generalized epilepsy. Mutations in both genes lead to genetic epilepsy with febrile seizures plus (GEFS+; Mendelian Inheritance in Man [MIM] 604233) (Escayg et al., 2000, 2001; Sugawara et al., 2001; Wallace et al., 2001b). This syndrome is also caused by mutations in the SCN1B gene encoding the sodium channel β1 subunit (Wallace et al., 1998, 2002) and two GABAA receptor genes: GABRG2 encoding the γ2 subunit (Baulac et al., 2001; Wallace et al., 2001a; Harkin et al., 2002) and GABRD encoding the δ subunit (Dibbens et al., 2004). SCN1A mutations are the main cause of both Dravet syndrome (DS, MIM 607208) and intractable childhood epilepsy with generalized tonic–clonic seizures, also known as severe idiopathic generalized epilepsy of infancy (Mulley et al., 2005; Fujiwara, 2006). SCN2A mutations cause benign familial neonatal–infantile seizures (BFNIS; MIM 607745) and some cases of DS (Kamiya et al., 2004; Ogiwara et al., 2009; Shi et al., 2009), and a mutation in SCN1B has also been identified in a patient with DS (Patino et al., 2009). One mutation in SCN3A (Nav1.3) has been reported in a patient with partial epilepsy (Holland et al., 2008). Interestingly, mutations in SCN9A, which is considered to be expressed predominantly in the peripheral nervous system, were recently identified in patients with febrile seizures. SCN9A might also serve as a genetic modifier of DS (Singh et al., 2009).
GEFS+ is an autosomal dominant disorder with a complex and heterogeneous clinical presentation (Scheffer & Berkovic, 1997; Singh et al., 1999). The syndrome was originally called generalized epilepsy with febrile seizures plus, which is misleading because the clinical phenotype also includes partial epilepsy. Therefore, the term autosomal dominant epilepsy with febrile seizures plus was proposed by Ito et al. (2002), and more recently Scheffer et al. (Scheffer et al., 2009; Ottman et al., 2010) proposed the alternative nomenclature genetic epilepsy with febrile seizures plus. Febrile seizures occur in approximately 3–5% of all children younger than 6 years of age and typically are not associated with increased risk of epilepsy in adolescence and adulthood (Nelson & Ellenberg, 1976; Commission on Classification Terminology of the International League Against Epilepsy, 1989). In contrast, patients with GEFS+ demonstrate febrile seizures that persist beyond 6 years of age and are associated with generalized or partial epilepsies, such as absence epilepsy, myoclonic seizures, atonic seizures, and myoclonic–astatic epilepsy (Scheffer & Berkovic, 1997; Singh et al., 1999). Affected individuals within GEFS+ families often display a wide variety of epilepsy subtypes, with markedly different ages of onset and severity, suggesting the action of genetic and/or environmental modifiers.
DS is a catastrophic early life epilepsy disorder in which the seizures are usually refractory to treatment and are associated with intellectual disability. This syndrome includes classical DS (severe myoclonic epilepsy of infancy) and borderline DS (severe myoclonic epilepsy of infancy borderline), in which patients show only a subset of clinical features (Mullen & Scheffer, 2009; Scheffer et al., 2009; Ottman et al., 2010). DS is characterized by febrile hemiclonic seizures or generalized status epilepticus starting at approximately 6 months of age, with other seizure types including partial, absence, atonic, and myoclonic seizures occurring after 1 year. In classical DS, development is delayed and patients often experience motor impairment, including spasticity and ataxia (Scheffer & Berkovic, 2003).
Genetics of SCN1A Mutations
Mutations in SCN1A account for approximately 10% of GEFS+ cases and mutations or deletions of SCN1A account for approximately 85% of DS cases (reviewed in Lossin, 2009; Claes et al., 2009). Updated lists of these mutations can be found at http://web.scn1a.info and http://www.molgen.ua.ac.be/SCN1AMutations/. Approximately 30 SCN1A-GEFS+ mutations have been identified to date. These have all been missense mutations (amino acid substitutions) that presumably alter but do not abolish SCN1A activity. In contrast, approximately half of the more than 600 SCN1A mutations in DS patients result from frameshift, nonsense, and splice-site mutations (reviewed in Lossin, 2009; Claes et al., 2009). Several of these mutations occur very early in the sequence of SCN1A, strongly suggesting that expression of the mutant allele is reduced or that a nonfunctional protein product is generated from the mutant allele, demonstrating haploinsufficiency of SCN1A (Meisler & Kearney, 2005; Catterall et al., 2008).
A large number of SCN1A missense mutations have also been identified in DS patients. It is likely that many of these also abolish channel function, possibly by altering the properties of the channel, trafficking or subcellular localization, or interactions with other molecules. Unlike GEFS+ mutations that segregate within affected families, most DS mutations are de novo in the affected child. In a recent study, Heron et al. (2009) demonstrated that these de novo mutations most frequently originate on the paternal chromosome. The greater number of mitoses during spermatogenesis compared with oogenesis and the susceptibility of the methylated DNA of sperm cells to acquire mutations likely account for this observation.
Adding to the complexity of untangling the molecular mechanisms involving SCN1A mutations, microdeletions within SCN1A, and sometimes extending to include as many as 49 contiguous genes, including SCN2A, SCN3A, and SCN9A, have also been found in approximately 2–3% of DS patients (Suls et al., 2006; Davidsson et al., 2008; Wang et al., 2008; Marini et al., 2009). Although some of these patients display additional dysmorphic features (Davidsson et al., 2008), their clinical presentation is often surprisingly indistinguishable from DS patients in whom only SCN1A is affected. This suggests that haploinsufficiency for the adjacent genes may not contribute significantly to the disease presentation. Partial duplication/amplification of SCN1A has also been identified in three DS patients (Marini et al., 2009). Because these copy number variations are not detected by standard polymerase chain reaction screening, the percentage of DS cases resulting from SCN1A mutations is most likely an underestimate. Marini et al. (2009) estimated a 2–3% frequency of chromosomal abnormalities causing DS, which still leaves approximately 15% of cases in which no abnormality of SCN1A has been identified. Only a small number of DS cases have been shown to be due to mutations in SCN1B, SCN2A, or GABRG2 (Harkin et al., 2002; Kamiya et al., 2004; Ogiwara et al., 2009; Patino et al., 2009; Shi et al., 2009), so the unexplained cases may be due to mutations in additional genes or may have polygenic etiologies (Marini et al., 2009).
Somatic and Germline Mosaicism
Although the majority of DS patients carry de novo SCN1A mutations, some cases have been described in which the mutation was inherited from an asymptomatic or mildly affected parent, suggesting that the expression of the mutation in the transmitting parent was modified by environmental and/or genetic factors or was the result of somatic mosaicism. Somatic and germline SCN1A mosaicism has been reported in a small number of cases (Depienne et al., 2006; Gennaro et al., 2006; Marini et al., 2006; Morimoto et al., 2006). The possibility of SCN1A mosaicism in the parents of children with DS should, therefore, be considered when performing genetic counseling and determining recurrent risk.
Genetic Modifiers in GEFS+ and DS
One of the characteristics of GEFS+ is that family members with the same SCN1A mutation often display a wide range of seizure types and severities, suggesting that additional environmental or genetic factors likely influence clinical presentation. As mentioned earlier, similar factors may also alter the severity of SCN1A-DS mutations that are sometimes inherited from an asymptomatic or mildly affected parent. Furthermore, it is likely that a subset of the identified SCN1A-DS missense mutations causes only a modest alteration in channel function, and additional inherited or de novo variants at other loci are required to produce the severe clinical presentation.
A number of studies are beginning to provide evidence for the involvement of genetic modifiers in GEFS+ and DS. We previously showed that mice with mutations in Scn8a display elevated thresholds to chemically induced seizures when compared with wild-type littermates (Martin et al., 2007). Interestingly, in the presence of an Scn8a mutation, normal seizure thresholds and life spans were restored in heterozygous Scn1a knockout mice, which serve as a model of DS (Martin et al., 2007). In a screen for genetic modifiers of DS, Ohmori et al. (2008) sequenced the coding exons of SCN1B, GABRG2, and CACNB4 in 38 SCN1A-positive DS patients. The amino acid substitution R468Q in CACNB4, the voltage-gated calcium channel β4 subunit, was identified in one individual. Increased calcium currents were seen when R468Q mutant channels were examined in BHK cells. Therefore, this mutation may result in increased neurotransmitter release from excitatory cells, which when combined with reduced inhibition as a result of the SCN1A mutation, may cause a more severe clinical presentation. Recently, Singh et al. (2009) proposed a role for SCN9A as a genetic modifier of DS. In that study, six DS patients who harbored missense or splice-site mutations in SCN1A were also found to carry SCN9A variants. This raises the possibility that alterations in SCN9A may exacerbate the impact of otherwise less deleterious SCN1A mutations on neuronal excitability.
Functional Effects of SCN1A Mutations
The biophysical effects of several SCN1A GEFS+ and DS mutations have been examined using heterologous expression systems. The locations of the mutations for which functional data are mentioned in this review are shown in Fig. 1. We characterized the effects of five GEFS+ mutations (R859C, T875M, W1204R, R1648H, and D1866Y) by expression in Xenopus oocytes (Spampanato et al., 2001, 2003, 2004; Barela et al., 2006), and other mutations have been characterized by expression in human embryonic kidney cells (HEK or tsA201) (Alekov et al., 2000, 2001; Lossin et al., 2002, 2003; Cossette et al., 2003). These mutations altered sodium channel activity in many different ways, with some of the effects predicted to either increase or decrease sodium channel activity (Table 1). For example, in oocyte expression studies, R1648H dramatically accelerated recovery from inactivation, W1204R shifted the voltage-dependence of activation and inactivation in the negative direction, R859C shifted the voltage-dependence of activation in the positive direction, and T875M enhanced slow inactivation. The alterations due to R1648H and W1204R are predicted to increase sodium channel function and neuronal excitability, whereas the alterations due to R859C and T875M should decrease channel function and neuronal excitability.
Table 1. Functional effects of the SCN1A sodium channel mutations that cause GEFS+
Increased sodium channel activity
↓ Use-dependence, faster recovery from slow inactivation
↓ Use-dependence, faster recovery
Decreased sodium channel activity
Positive voltage-dependence, slower recovery from slow inactivation, ↓ current
↑ Slow inactivation
↑ Fast and slow inactivation
No sodium current
Positive voltage-dependence, ↓ current
No sodium current
The observed functional effects of SCN1A mutations are also influenced by the expression system. For example, the most prominent effect of R1648H, W1204R, and T1875M in tsA201 cells was an increase in the level of persistent current, with a marked increase for R1648H and a slight increase for T875M and W1204R (Lossin et al., 2002). The increased persistent current resulting from the R1648H mutation was due to a higher probability of late reopening and a fraction of channels with prolonged open times (Vanoye et al., 2006). It was previously shown in a transgenic Scn2a mouse model that increased persistent current can lead to seizures (Kearney et al., 2001), so a reasonable hypothesis was that this is the physiologic change that causes seizures in GEFS+ (Cannon, 2002; Lossin et al., 2002).
Taken together, the data from the heterologous expression systems failed to uncover a consistent mechanism of pathogenesis and suggested that SCN1A mutations causing either gain-of-function or loss-of-function in Nav1.1 can predispose the CNS to abnormal excitability. However, this conclusion assumes that the effects of the mutations in heterologous systems are a direct reflection of their effects in native neurons, which may not be the case for a number of reasons (Ragsdale, 2008). First, the specific β subunits that are present in each type of neuron (β1 or β3 and β2 or β4) could alter the properties of the sodium channels, and hence the effects of the mutations. Second, the GEFS+ mutations could alter aspects of channel processing or trafficking that may be unique to neurons, so that the physiologically relevant phenotype would not be seen in another cell type. Third, neurons express multiple sodium channel isoforms, as well as an array of other voltage- and ligand-gated ion channels. The repertoire of channels can have a dramatic effect on the properties of a mutation, as has been shown for an SCN9A mutation that causes erythermalgia, and which made sympathetic neurons hypoexcitable but sensory neurons hyperexcitable because of the presence of Nav1.8 (Rush et al., 2006). Finally, studies in heterologous systems cannot reveal whether the mutations primarily affect excitatory or inhibitory neurons. A comparable alteration in sodium channel function in excitatory or inhibitory neurons is likely to have opposite effects on network excitability. For these reasons, it is essential to determine the effects of the mutations in native neurons in which SCN1A is normally expressed. This can be done most effectively using genetic mouse models.
Mouse Models of Human SCN1A Syndromes
Two different mouse models of DS have been constructed and analyzed (Table 2). Yu et al. (2006) constructed a mouse model of DS by targeted disruption of the mouse Scn1a gene. Heterozygous mutants (Scn1a+/−) with 50% of normal Nav1.1 levels were found to exhibit spontaneous seizures, reduced thresholds to hyperthermia-induced seizures, and a high mortality rate from 4 weeks after birth (Yu et al., 2006; Oakley et al., 2009). Homozygous mutants, which completely lack Nav1.1, were ataxic and died 15 days after birth. Electrophysiologic analysis of hippocampal pyramidal neurons from homozygous Scn1a knockout mice revealed normal levels of sodium currents, indicating that Nav1.1 does not contribute significantly to sodium currents in these neurons. In contrast, sodium currents were reduced significantly in hippocampal interneurons that are critical for GABA-mediated neuronal inhibition. In addition, GABAergic cerebellar Purkinje neurons demonstrated significantly decreased peak, persistent, and resurgent sodium currents, which is a likely explanation for the severe ataxia in these mice (Kalume et al., 2007). The Scn1a knockout mice were also found to have a compensatory increase in Nav1.3 expression. This was an unexpected finding, because Nav1.3 is highly expressed in the developing embryo, but decreases to almost undetectable levels in the adult mouse. It is not clear what role the increased Nav1.3 expression plays in the pathogenesis of epilepsy in these mice.
Table 2. Mouse models of human epilepsy caused by SCN1A mutations
Type of model
Spontaneous seizures, febrile seizures, ataxia, and death at P15 in homozygous mice
Infrequent spontaneous seizures, reduced seizure thresholds, and accelerated propagation of febrile seizures in heterozygous mice
Slower recovery from inactivation, greater use-dependent inactivation, reduced sodium current density, and decreased action potential firing in bipolar inhibitory neurons
The second mouse model of DS was constructed by Ogiwara et al. (2007), who incorporated into the mouse Scn1a gene a premature stop codon (R1407X) that was found in three human patients. Both homozygous and heterozygous mice demonstrated decreased Nav1.1 expression and spontaneous seizures. Wild-type Nav1.1 channels were observed to cluster primarily at the axon initial segments of parvalbumin-positive interneurons, and trains of action potentials in these neurons from the mutant mice demonstrated decreased amplitudes late in the burst. The results from both knockout mouse models are consistent and suggest that a reduction in neuronal inhibition contributes to the severe seizures associated with DS.
To examine the effects of a GEFS+ SCN1A mutation on channel function in vivo, we generated mice carrying the R1648H mutation (Table 2), which was previously shown to decrease use-dependent inactivation in Xenopus oocytes (Spampanato et al., 2001) and increase persistent current in tsA201 cells (Lossin et al., 2002). To determine how the mutation affected sodium channel function in neurons, we first generated a bacterial artificial chromosome (BAC) transgenic mouse model (Tang et al., 2009). This model had two advantages for these studies. First, the transgene included the entire Scn1a gene, so it was likely to be regulated and expressed in the same neurons as the native channels. Second, the transgene was engineered to also include the E954Q substitution that makes the channel resistant to tetrodotoxin (TTX) and saxitoxin (STX) (Kontis & Goldin, 1993). The predominant sodium channels in the mammalian CNS are all blocked by nanomolar concentrations of TTX or STX, so the R1648H mutant channels could be studied in isolation by recording in the presence of either of these toxins.
The effects of the R1648H mutation depended on the neurons in which it was studied. In inhibitory neurons from the BAC transgenic mice, the mutation caused delayed recovery from inactivation and increased use-dependent inactivation, which is the exact opposite of the effects that were observed in oocytes (Spampanato et al., 2001). In addition, there was no detectable increase in persistent current, unlike the findings in tsA201 cells (Lossin et al., 2002). In contrast, mutant sodium channels in excitatory pyramidal neurons showed no alteration in use-dependent inactivation or recovery from inactivation, but they did have a negative shift in the voltage dependence of inactivation. In addition, the mutation decreased the total sodium current amplitude in bipolar neurons, but it did not affect the current amplitude in pyramidal neurons, further suggesting a specific impairment of inhibitory function. The BAC transgenic mice did not exhibit spontaneous seizures, but they did have a more severe response to the proconvulsant kainic acid compared with mice expressing a control Scn1a transgene.
To more accurately model the human disorder, we also introduced the R1648H mutation into the orthologous mouse gene by constructing a knock-in mouse model of GEFS+ (Martin et al., 2010). Mice homozygous for the R1648H mutation (Scn1aRH/RH) exhibited spontaneous generalized seizures and premature death between P16 and P26, whereas heterozygous mutants (Scn1aRH/+) exhibited infrequent spontaneous generalized seizures, reduced threshold and accelerated propagation of hyperthermia-induced seizures, and decreased threshold to flurothyl-induced seizures. Inhibitory cortical interneurons from P5-P15 Scn1aRH/+ and Scn1aRH/RH mice demonstrated slower recovery from inactivation and greater use-dependent inactivation compared with wild-type cells. In contrast, excitatory cortical pyramidal neurons demonstrated slightly faster recovery from inactivation. The R1648H mutation specifically decreased the total sodium current amplitude in bipolar neurons, consistent with the results from the BAC transgenic mice (Tang et al., 2009).
The alteration in sodium channel properties in bipolar neurons from the knock-in mice had a significant effect on the excitability of those cells and would most likely result in decreased inhibition. Bipolar neurons from Scn1aRH/RH mice fired a maximum of 20 action potentials in response to a 2-s injection of 70-pA current, whereas bipolar neurons from wild-type and Scn1aRH/+ mice fired approximately 35 action potentials in response to the same stimulus. Pyramidal neurons from all three genotypes fired similar numbers of action potentials over the range of currents injected, with the exception of Scn1aRH/RH mice, which showed reduced numbers when 30–50 pA of current was injected. However, since the number of action potentials was comparable for higher levels of current (≥ 70 pA), it is unclear whether the difference at lower levels of current is physiologically significant. Reduced inhibition is consistent with the rapid, abnormal propagation of experimental febrile seizures in these mice. Most Scn1aRH/RH mutants became immobile (the typical onset of the experimental febrile seizure), and then immediately progressed to a tonic seizure. This progression was rarely seen in wild-type or Scn1aRH/+ mice and, when evident, took several minutes to occur.
The results from both the BAC transgenic and knock-in mouse models suggest that the primary effect of the R1648H GEFS+ mutation is to specifically impair interneuron sodium channel activity, leading to decreased inhibition. Given the importance of inhibitory circuits in controlling the excitability of postsynaptic neurons, it seems likely that reduced firing of cortical interneurons, and possibly other GABAergic interneurons, contributes to seizure generation in the Scn1aR1648H mouse models. This model is consistent with the fact that mutations of GABAA receptor genes GABRG2, GABRD, GABRA1, and GABRB3 cause GEFS+, DS, and childhood absence epilepsy by decreasing either the function or number of GABAA receptors (Kang & Macdonald, 2009).
Mutations in the genes encoding voltage-gated sodium channels cause a variety of epilepsy syndromes in humans, with most of the mutations occurring in SCN1A. All of these mutations are dominant, and they can result in either loss of function (most commonly observed in DS) or altered function (most commonly observed in GEFS+). Based on the analysis of mouse models of these two syndromes, decreased activity of the inhibitory circuitry is likely a major factor contributing to seizure generation in the mice, and, by extension, in GEFS+ and DS patients. Impairment of inhibition could be a general effect of SCN1A mutations causing epilepsy, although the analysis of mouse models with other Scn1a mutations is needed to determine whether this is a consistent mechanism. While this review was in press, Mashimo et al. (2010) reported the generation of a rat model carrying the N1417H substitution located in the third pore region of Scn1a. In agreement with observations from the mouse models, the mutant rats exhibited increased susceptibility to hyperthermia-induced seizures and altered sodium channel properties in interneurons.
We are grateful to Cheryl Strauss for editorial assistance. Research in the authors’ laboratories is supported by grants from the NIH (NS065187 to AE and ALG, NS046484 and NS066155 to AE, NS048336 to ALG), the McKnight Foundation (34653 to ALG), and the Epilepsy Foundation (AE).
Andrew Escayg has received support from and has served as a paid consultant for Allergan and Alan Goldin has received support from and has served as a paid consultant for Allergan. We confirm that we have read the Journal’s position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.